Clomiphene citrate raw powder: Is it possible to get pregnancy fast by Clomiphene citrate?(1)

www.aasraw.com

Clomiphene citrate raw powder: Is it possible to get pregnancy fast by Clomiphene citrate?(1)

ǀ.Clomiphene citrate/Clomid basic Characters: Name: Clomiphene citrate/Clomid CAS: 50-41-9 Molecular Formula:C32H36ClNO8 Molecular Weight: 598.08 Melt Point: 116.5-118°C Storage Temp: 2-8°C Color: White crystalline powder

1.What is Clomiphene citrate?

Clomiphene citrate powder is a non-steroidal fertility medicine. It causes the pituitary gland to release hormones needed to stimulate ovulation (the release of an egg from the ovary).

Clomiphene citrate is used to cause ovulation in women with certain medical conditions (such as polycystic ovary syndrome) that prevent naturally occurring ovulation.Clomiphene citrate may also be used for purposes not listed in this medication guide.

1

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

2.You know: Clomiphene citrate mechanism of action Clomiphene citrate was recently reclassified as a selective-estrogen receptor-modulator (SERM) due to its ability to compete with estradiol for estrogen receptors at the level of the hypothalamus. Clomiphene citrate blocks the normal negative feedback of circulating estradiol on the hypothalamus, preventing estrogen from lowering the output of gonadotropin releasing hormone (GnRH).

During Clomiphene citrate therapy, the frequency and amplitude of GnRH pulses increase and stimulate the pituitary gland to release more FSH and LH. In turn, FSH and LH stimulate the ovaries to develop oocyte follicles. Clomiphene citrate may allow several oocytes to develop to maturity in some patients. Estrogen produced by the maturing follicles causes the cervical mucus to thin and the endometrium to proliferate.

As the estradiol from these follicles rises, the positive feedback to the pituitary causes the FSH/LH surge and is followed by mature oocyte release (ovulation). Once ovulation occurs, the corpus luteum forms, and progesterone levels rise as they do in a regular ovulatory cycle, and prepare the endometrium for implantation. Clomiphene citrate must be used before the time of normal selection of the dominant follicle in an ovulatory cycle. The “traditional” timing of Clomiphene citrate treatment is from follicular phase cycle day 5 through 9; women typically ovulate 5—10 days after the last dose of the cycle.

However, earlier initiation of treatment, longer courses (i.e., up to 10 days), or higher Clomiphene citrate doses may be needed dependent on the ovulatory response of the individual woman.

2

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

Clomiphene citrate is also a weak estrogen-agonist and may interact with estrogen-receptor containing tissues, including the ovary, endometrium, vagina, and cervix. In the cervix, Clomiphene citrate can interfere with the ability of cervical mucus glands to produce thin secretions that favor sperm motility and conception. In some women, Clomiphene citrate may induce dry, thick cervical secretions.

Studies are ongoing to assess the activity of Clomiphene citrate on breast tissues. The estrogenic effects of Clomiphene citrate are secondary to the primary effects on hypothalamic-pituitary-ovarian function. Clomiphene citrate exhibits no androgenic, anti-androgenic, or progestational effects, nor does it affect pituitary-thyroid or pituitary-adrenal function. After Clomiphene citrate therapy discontinuation, there is usually no continued pharmacological effect on subsequent menstrual cycles. However, in some females, spontaneous ovulation has continued.

3

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

In selected female patients, Clomiphene citrate therapy is augmented by other medications to increase the occurrence of successful ovulation or pregnancy. These medications have included: dexamethasone for hirsutism or hyperandrogenism; estradiol to offset the cervical mucus-thickening effect of Clomiphene citrate; human chorionic gonadotropin (HCG) to induce the LH-surge for ovulation; and the use of metformin or troglitazone to offset the hyperinsulinemia that occurs in some patients with polycystic ovaries.

Octreotide has been used as an adjunct to Clomiphene citrate therapy in patients with polycystic ovaries in order to reduce androgen secretion, decrease LH levels, and potentially decrease the incidence of ovarian hyperstimulation. The mechanisms of action of these drugs are distinct from Clomiphene citrate and do not appear to change the pharmacokinetics of clomiphene treatment. The regimens of each of these augmenting medications requires careful monitoring and timing of administration under the prescription of a healthcare professional experienced in fertility and endocrinology.

In men with idiopathic oligospermia, Clomiphene citrate may be effective at stimulating GnRH release from the hypothalamus, thus increasing the levels of LH and FSH released from the pituitary.

LH and FSH then apparently stimulate the testicles to produce testosterone and sperm. Sperm volume and density are increased; however, Clomiphene citrate may not increase sperm maturation or motility.

4

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com